Drugs / BPI-452080
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05843305 | Apr 2023 → Mar 2025 | renal cell carcinoma, von Hippel-Lindau disease | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPI-452080 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05843305 ↗ |
| Route | Oral | “Oral tablets taken in escalating levels to determine MTD/RP2D.” NCT05843305 ↗ |